CT45 Protein Predicts Longer Survival Times in Advanced-stage Ovarian Cancer, Study Reports

CT45 Protein Predicts Longer Survival Times in Advanced-stage Ovarian Cancer, Study Reports
A protein called CT45 predicts which ovarian cancer patients will respond to platinum-based chemotherapy and is associated with extended survival in these patients, being a new prognostic marker for ovarian cancer, a study shows. The findings also suggest that strategies boosting CT45 levels could improve chemotherapy's efficacy. The research, “Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer,” appeared in the journal Cell. About 15% of women with high-grade serous ovarian cancer (HGSOC) — the most common subtype of ovarian cancer — do not experience a recurrence of their disease and remain disease-free for over a decade after aggressive treatments with surgery and platinum-based chemotherapy. Aiming to discover what drives long-term survival in these patients, a collaboration between the University of Chicago Medicine, the Max Planck Institute of Biochemistry in Germany, and the Novo Nordisk Foundation Center for Protein Research in Denmark used an analytical technique called mass spectrometry to conduct a large-scale protein analysis (proteomics) in ovarian tissue samples of platinum-resistant and platinum-sensitive HGSOC patients. "Our highly sensitive methods now enable us to profile thousands of proteins simultaneously, allowing us to search for the proteins that are critical to the disease," M
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *